• news.cision.com/
  • H. Lundbeck A/S/
  • Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

Report this content

Valby, Denmark, July 12, 2022 – H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

In connection with the split of Lundbeck’s existing shares into A-shares and B-shares completed in June 2022, the Lundbeck Foundation (via its fully owned subsidiary Lundbeckfond Invest A/S)(the Foundation) offered eligible shareholders a 1:1 exchange of their A-shares with the Lundbeck Foundation’s B-shares. In accordance with Article 19 of Regulation No. 596/2014 on market abuse, Lundbeck is required to report transactions made by executives and their closely associated parties. This includes the number of shares exchanged.

Following the completion of the exchange offer, the Foundation now holds approximately 80 % of the A-shares and approximately 66 % of the B-shares. The total share capital held by the Foundation is approximately 69 % and the total voting rights held by the Foundation in Lundbeck is approximately 76 %.
 

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Lundbeckfond Invest A/S
2. Reason for the notification
a) Position/status Closely associated party due to Lene Skole-Sørensen’s capacity as Deputy Chair of Lundbeck and CEO of Lundbeckfond Invest A/S
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesDK0061804697 (A-shares)DK0061804770 (B-shares)
b) Nature of the transaction Exchange of shares. The volume number indicated below is the number of Lundbeckfond Invest A/S’ B-shares exchanged in return for other shareholders’ A-shares. 
c) Price(s) and volume(s) Price(s) Volume(s)
DKK  0 22,743,609
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2022-07-09
f) Place of the transaction Outside a trading venue
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Lene Skole-Sørensen
2. Reason for the notification
a) Position/status Deputy Chair of the Board of Directors of H. Lundbeck A/S
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesDK0061804697 (A-shares)DK0061804770 (B-shares)
b) Nature of the transaction Exchange of shares. The volume number indicated below is the number of B-shares received from Lundbeckfond Invest A/S in return for A-shares.
c) Price(s) and volume(s) Price(s) Volume(s)
DKK  0 DKK  12,254
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2022-07-09
f) Place of the transaction Outside a trading venue
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Lars Erik Holmqvist
2. Reason for the notification
a) Position/status Member of the Board of Directors of H. Lundbeck A/S
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesDK0061804697 (A-shares)DK0061804770 (B-shares)
b) Nature of the transaction Exchange of shares. The volume number indicated below is the number of B-shares received from Lundbeckfond Invest A/S in return for A-shares.
c) Price(s) and volume(s) Price(s) Volume(s)
DKK  0 DKK  15,000
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2022-07-09
f) Place of the transaction Outside a trading venue

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.

Lundbeck contacts

Investors:                                    Media:
Palle Holm Olesen Juliane Lenzner
Vice President, Investor Relations Vice President, Corporate Communication
PALO@lundbeck.com JULZ@lundbeck.com
+45 30 83 24 26 +45 36 43 40 00

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases – we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.